Q2 2026

Financial Report

Comments from Mattias Perjos, CEO

Healthy organic growth, high profitability and strong cash flow

"We delivered a strong quarter both financially and operationally with several key achievements. Sales in Acute Care Therapies increased in most product categories, and the positive trend in consumables for life-supporting ECLS therapy was maintained. Surgical Workflows continued to display good momentum. The situation in Life Science remains mixed – the high-margin category of Sterile Transfer reported double-digit growth for both its order intake and sales. However, the pharma sector's willingness to invest remains dominated by geopolitical uncertainty, which can primarily be seen in the project-based and capital-intense product category of WIS.

The adjusted EBITA margin was 17.6%, positively impacted by a tariff refund of approximately SEK 336 M, as well as by a continued positive underlying performance in the operations featuring a favorable mix, continued price adaptations and productivity improvements – which also led to a clear improvement in cash flow. Excluding the net effect of tariffs (SEK+244 M) and currency effects compared to last year (SEK -73 M), the adjusted EBITA margin was 15.2 %.

Innovation focusing on customer value is vital for us at Getinge, and we launched several products during the quarter that strengthen our offering. One example is a new product generation within Endoscopic Vessel Harvesting (EVH). In addition, a system for increased capacity and enhanced safety in automated endoscope reprocessing was launched and a product expanding the fluorescence imaging portfolio for small-incision surgery. A key regulatory milestone was achieved alongside these launches when the 510(k) application for the Cardiosave intra-aortic balloon pump was submitted to the FDA in June.

We also strengthen our infection prevention offering in endoscopy by the acquisition of Pennamed, a UK-based distributor of endoscopic consumables. In addition, we opened a new innovation center in Hamburg that seeks to accelerate the path to a more intelligent, digital perioperative workflow.

Overall, we are well positioned in the prioritized product categories of our customers, which gives us confidence for the future. While geopolitical uncertainty remains, based on our regular dialogue with customers, we maintain our forecast of organic sales growth of 3–5% in 2026."

April – June 2026 in brief

- Net sales increased organically by 4.6% (4.1) and the order intake rose by 6.2% organically (4.4)
- Adjusted gross profit amounted to SEK 4,645 M (4,183) and the margin was 55.4% (50.8)
- Adjusted EBITA was SEK 1,478 M (989) and the margin 17.6% (12.0)
- Adjusted earnings per share amounted to SEK 3.59 (2.25)
- Free cash flow amounted to SEK 1 001 M (510)

January – June 2026 in brief

- Net sales increased organically by 2.7% (5.1) and the order intake rose by 5.0% organically (3.6)
- Adjusted gross profit amounted to SEK 8,473 M (8,519) and the margin was 53.5% (51.5)
- Adjusted EBITA was SEK 2,302 M (1,992) and the margin 14.5% (12.0)
- Adjusted earnings per share amounted to SEK 5.39 (4.43)
- Free cash flow amounted to SEK 1 843 M (670)

Outlook 2026: Net sales for 2026 are expected to increase by 3–5% organically, adjusted for the phase-out of Surgical Perfusion[1] (Unchanged)

Summary of financial performance[2]

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Order intake	**8,668**	**8,361**	**16,607**	**16,993**	**33,639**	**34,025**
Organic change, %	*6.2*	*4.4*	*5.0*	*3.6*		*3.5*
Net sales	**8,381**	**8,238**	**15,824**	**16,557**	**34,236**	**34,969**
Organic change, %	*4.6*	*4.1*	*2.7*	*5.1*		*4.9*
Adjusted gross profit	**4,645**	**4,183**	**8,473**	**8,519**	**17,561**	**17,607**
Margin, %	*55.4*	*50.8*	*53.5*	*51.5*	*51.3*	*50.4*
Adjusted EBITDA	**1,893**	**1,410**	**3,115**	**2,852**	**6,844**	**6,581**
Margin, %	*22.6*	*17.1*	*19.7*	*17.2*	*20.0*	*18.8*
Adjusted EBITA	**1,478**	**989**	**2,302**	**1,992**	**5,190**	**4,880**
Margin, %	*17.6*	*12.0*	*14.5*	*12.0*	*15.2*	*14.0*
Adjusted EBIT	**1,384**	**895**	**2,122**	**1,791**	**4,825**	**4,494**
Margin, %	*16.5*	*10.9*	*13.4*	*10.8*	*14.1*	*12.9*
Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**4,315**	**3,789**
Margin, %	*15.3*	*10.5*	*12.6*	*8.9*	*12.6*	*10.8*
Profit before tax	**1,151**	**721**	**1,724**	**1,149**	**3,720**	**3,145**
Net profit for the period	**839**	**527**	**1,242**	**831**	**2,687**	**2,276**
Adjusted net profit for the period	**976**	**616**	**1,466**	**1,213**	**3,347**	**3,093**
Margin, %	*11.6*	*7.5*	*9.3*	*7.3*	*9.8*	*8.8*
Adjusted earnings per share, SEK	**3.59**	**2.25**	**5.39**	**4.43**	**12.25**	**11.29**
Earnings per share, SEK	**3.09**	**1.92**	**4.56**	**3.02**	**9.83**	**8.29**
Cash flow from operating activities	**1,291**	**841**	**2,398**	**1,311**	**5,036**	**3,949**
Free cash flow	**1,001**	**510**	**1,843**	**670**	**3,825**	**2,652**

1) For more information about the adjustment of the Organic change key ratio, refer to Other information on page 9
2) See page 3 for calculations of adjusted performance measures

Group performance

Order intake

- The organic order intake for Acute Care Therapies increased, primarily in ECLS therapy consumables, stents and EVH.
- Life Science's organic order intake rose sharply during the quarter, following double-digit growth in Sterile Transfer and Bio-Processing. WIS continued to decline as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
- The organic order intake for Surgical Workflows increased slightly, driven by a strong performance in Infection Control, while Digital Health Solutions and Surgical Workplaces noted a decline.
- Geographically, the organic order intake trend was positive in all regions, except for APAC where the order intake declined in China and Japan.

Order intake business areas, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Acute Care Therapies	4,490	4,382	*6.2*	8,747	9,307	*2.3*	17,660	18,220
Life Science	1,240	1,054	*20.8*	2,148	2,032	*12.2*	4,368	4,252
Surgical Workflows	2,938	2,924	*1.1*	5,712	5,655	*6.9*	11,611	11,553
Total	**8,668**	**8,361**	***6.2***	**16,607**	**16,993**	***5.0***	**33,639**	**34,025**

Order intake regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	3,947	3,768	*8.2*	7,626	7,853	*6.2*	15,202	15,429
APAC	1,558	1,636	*-2.2*	2,965	3,167	*1.8*	6,108	6,311
EMEA	3,164	2,956	*8.4*	6,016	5,973	*5.3*	12,328	12,285
Total	**8,668**	**8,361**	***6.2***	**16,607**	**16,993**	***5.0***	**33,639**	**34,025**

Net sales

- Acute Care Therapies increased its net sales organically, primarily due to sales of stents, ECLS therapy consumables, as well as intra-aortic balloon pumps and consumables in the Cardiac Assist segment.
- Organic net sales for Life Science fell slightly despite robust growth in all product categories, except for WIS.
- In Surgical Workflows, organic net sales rose following growth in Surgical Workplaces as well as service and consumables in Infection Control.
- Positive organic growth in EMEA, with particularly strong sales in Poland and France. Sales also increased in Americas, driven by growth in the US, yet declined in APAC.
- Recurring revenue increased in the quarter following growth in, for example, ECLS therapy and Sterile Transfer. Sales of capital goods declined in the quarter, above all related to WIS in Life Science.

Net sales business areas, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Acute Care Therapies	4,552	4,480	*6.0*	8,565	9,255	*0.8*	17,985	18,675
Life Science	1,101	1,123	*-0.2*	2,104	2,073	*7.2*	4,529	4,498
Surgical Workflows	2,727	2,634	*4.3*	5,155	5,229	*4.1*	11,722	11,796
Total	**8,381**	**8,238**	***4.6***	**15,824**	**16,557**	***2.7***	**34,236**	**34,969**

Net sales regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	3,875	3,847	*4.0*	7,328	7,894	*1.3*	15,119	15,686
APAC	1,486	1,553	*-1.1*	2,842	3,195	*-3.1*	6,590	6,943
EMEA	3,020	2,838	*8.6*	5,655	5,468	*8.0*	12,527	12,340
Total	**8,381**	**8,238**	***4.6***	**15,824**	**16,557**	***2.7***	**34,236**	**34,969**

Net sales specified by capital goods and recurring revenue, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Capital goods	2,495	2,629	*-2.3*	4,573	5,110	*-4.5*	11,431	11,968
Recurring revenue1)	5,886	5,609	*7.8*	11,251	11,448	*5.9*	22,805	23,001
Total	**8,381**	**8,238**	***4.6***	**15,824**	**16,557**	***2.7***	**34,236**	**34,969**

1) Consumables, service and spare parts

Net sales – bridge between Q2 2025 and Q2 2026

- Net sales increased by SEK 143 M, corresponding to 1.7%.
- Exchange rates had an impact of SEK -206 M on sales, corresponding to -2.5%.
- Successful efforts with price adjustments and volumes had an impact of SEK +374 M on sales, corresponding to +4.5%.



Earnings trend

- Currency effects impacted adjusted gross profit by SEK -125 M and adjusted EBITA by SEK -73 M compared with last year.
- Adjusted gross profit increased by SEK 462 M, of which the tariff refund had an impact of approximately SEK +336 M and tariff costs of approximately SEK -92 M (Q2 2025: -SEK -110M). Coupled with continued successful price adjustments, productivity and a positive mix, the margin improved by 4.6 percentage points.
- Adjusted EBITA increased by SEK 489 M, primarily due to improved gross profit. The margin increased by 5.6 percentage points.
- Acquisition and restructuring costs are primarily related to the ongoing rationalizations in the organization.
- Net financial items decreased to SEK -133 M, mainly as a result of lower average interest year-on-year.
- The tax rate for the first two quarters of the year was 28.0%.

	SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
	Net sales	8,381	8,238	15,824	16,557	34,236	34,969
	Adjusted gross profit	**4,645**	**4,183**	**8,473**	**8,519**	**17,561**	**17,607**
	Margin, %	*55.4*	*50.8*	*53.5*	*51.5*	*51.3*	*50.4*
	Adjusted operating expenses	-2,752	-2,772	-5,359	-5,667	-10,717	-11,026
	Adjusted EBITDA	**1,893**	**1,410**	**3,115**	**2,852**	**6,844**	**6,581**
	Margin, %	*22.6*	*17.1*	*19.7*	*17.2*	*20.0*	*18.8*
	Depreciation, amortization and write-downs of intangible assets and tangible assets[1]	-415	-421	-813	-860	-1,654	-1,702
	Adjusted EBITA	**1,478**	**989**	**2,302**	**1,992**	**5,190**	**4,880**
	Margin, %	*17.6*	*12.0*	*14.5*	*12.0*	*15.2*	*14.0*
A	Amortization and write-down of acquired intangible assets[1]	-93	-94	-180	-201	-365	-386
	Adjusted EBIT	**1,384**	**895**	**2,122**	**1,791**	**4,825**	**4,494**
	Margin, %	*16.5*	*10.9*	*13.4*	*10.8*	*14.1*	*12.9*
B	Acquisition and restructuring costs	-68	-28	-98	-325	-170	-397
C	Other items affecting comparability[2]	-33	-	-33	-	-340	-307
	Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**4,315**	**3,789**
	Net financial items	-133	-147	-267	-317	-595	-644
	Profit before tax	**1,151**	**721**	**1,724**	**1,149**	**3,720**	**3,145**
	Adjusted profit before tax (adjusted for A, B and C)	**1,345**	**842**	**2,035**	**1,675**	**4,595**	**4,236**
	Margin, %	*16.0*	*10.2*	*12.9*	*10.1*	*13.4*	*12.1*
	Taxes	-312	-194	-482	-318	-1,034	-869
D	Tax on adjustment items[2]	-57	-33	-86	-145	-215	-273
	Adjusted net profit for the period (adjusted for A, B, C and D)	**976**	**616**	**1,466**	**1,213**	**3,347**	**3,093**
	Margin, %	*11.6*	*7.5*	*9.3*	*7.3*	*9.8*	*8.8*
	Of which, attributable to Parent Company shareholders	978	613	1,467	1,205	3,337	3,076
	Average number of shares, thousands	**272,370**	**272,370**	**272,370**	**272,370**	**272,370**	**272,370**
	Adjusted earnings per share, SEK (adjusted for A, B, C and D)	**3.59**	**2.25**	**5.39**	**4.43**	**12.25**	**11.29**

1) Excluding items affecting comparability (see Note 4 Depreciation, amortization and write-downs)
2) See Note 6 Adjustment items

Adjusted EBITA per business area[1]

- Adjusted EBITA for Acute Care Therapies rose by SEK 354 M, mainly due to a tariff refund, higher sales and continued successful price adjustments. The margin increased by 7.5 percentage points.
- Life Science's adjusted EBITA increased by SEK 23 M, mainly attributable to a favorable mix, price adjustments and tariff refunds. The margin increased by 2.3 percentage points.
- Adjusted EBITA for Surgical Workflows increased by SEK 96 M, mainly due to the tariff refund, price adjustments and higher sales. The margin improved by 3.3 percentage points.
- Costs in Group functions and other were slightly lower year-on-year.

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Acute Care Therapies	**1,202**	**848**	**1,965**	**1,860**	**3,868**	**3,763**
Margin, %	*26.4*	*18.9*	*22.9*	*20.1*	*21.5*	*20.2*
Life Science	**146**	**123**	**243**	**176**	**556**	**490**
Margin, %	*13.3*	*11.0*	*11.5*	*8.5*	*12.3*	*10.9*
Surgical Workflows	**237**	**141**	**312**	**190**	**1,200**	**1,077**
Margin, %	*8.7*	*5.4*	*6.1*	*3.6*	*10.2*	*9.1*
Group functions and other (incl. eliminations)	-108	-124	-218	-234	-434	-450
Total	**1,478**	**989**	**2,302**	**1,992**	**5,190**	**4,880**
Margin, %	*17.6*	*12.0*	*14.5*	*12.0*	*15.2*	*14.0*

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Adjusted EBITA – bridge between Q2 2025 and Q2 2026



- Adjusted operating expenses for selling and administration increased by 4.0%. Organically they increased by 5.8%, mainly due to higher sales activities.
- The year-on-year difference for other operating income and expenses was mainly attributable to currency effects related to operating receivables and liabilities in foreign currency.

Adjusted operating expenses

(excluding depreciation, amortization and write-downs and other items affecting comparability)[1]

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Selling expenses	-1,345	-1,317	-2,622	-2,722	-5,245	-5,345
Administrative expenses	-1,103	-1,035	-2,136	-2,110	-4,208	-4,182
Selling and administrative expenses	**-2,447**	**-2,352**	**-4,758**	**-4,832**	**-9,453**	**-9,527**
Research and development costs	-337	-326	-646	-626	-1,264	-1,244
Other operating income and expenses	33	-94	45	-209	-1	-255
Total	**-2,752**	**-2,772**	**-5,359**	**-5,667**	**-10,717**	**-11,026**

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

- Costs for R&D were 3.8% lower year-on-year.
- Capitalized development costs were 17.5% lower compared with last year.
- The year-on-year difference was mainly due to lower costs for quality-related efforts.
- Amortization and write-down of capitalized development costs amounted to SEK -86 M (-100), of which SEK -1 M write-down (-).

Research and development

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Research and development costs	-478	-497	-941	-973	-1,889	-1,921
Amortization, depreciation and write-downs	-21	-17	-40	-34	-181	-175
Research and development costs, gross	**-499**	**-514**	**-982**	**-1,008**	**-2,070**	**-2,096**
In relation to net sales, %	*6.0*	*6.2*	*6.2*	*6.1*	*6.0*	*6.0*
Capitalized development costs	**141**	**171**	**295**	**347**	**592**	**643**
In relation to net sales, %	*1.7*	*2.1*	*1.9*	*2.1*	*1.7*	*1.8*
Research and development costs, net	**-358**	**-343**	**-686**	**-661**	**-1,478**	**-1,452**
Amortization and write-down of capitalized development costs[1]	**-86**	**-100**	**-170**	**-200**	**-400**	**-430**

1) Capitalized development projects

- Exchange-rate fluctuations, meaning translation and transaction effects, impacted adjusted gross profit by SEK -125 M compared with last year, of which SEK -132 M in translation effects and SEK +7 M in transaction effects.
- The change in adjusted EBITA attributable to currency effects was SEK -73 M, of which SEK -73 M arose from translation effects and SEK 0.2 M from the net of transaction effects, and revaluation of operating receivables and liabilities in foreign currency.

Currency impact

SEK M	Apr-Jun 2026	Jan-Jun 2026	R12 Jun 2026
Net sales	-206	-1,107	-2,726
Adjusted gross profit	-125	-668	-1,574
Adjusted EBITDA	-79	-232	-736
Adjusted EBITA	-73	-194	-639
Adjusted EBIT	-70	-178	-606

- Free cash flow essentially doubled compared with last year. It was positively impacted by the strong operating profit and changes in working capital.
- The financial position remains solid.

Cash flow and financial position[1]

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Cash flow before changes in working capital	1,466	1,054	2,330	2,186	5,281	5,137
Changes in working capital	-174	-213	67	-875	-246	-1,188
Net investments in non-current assets	-291	-331	-555	-641	-1,211	-1,297
Free cash flow	**1,001**	**510**	**1,843**	**670**	**3,825**	**2,652**
Net interest-bearing cash/debt			**11,492**	**11,724**	**11,492**	**9,840**
In relation to adjusted EBITDA[1] *R12M, multiple*			*1.7*	*1.7*	*1.7*	*1.5*
Net interest-bearing cash/debt, excl. pension provisions			**9,049**	**9,244**	**9,049**	**7,482**
In relation to adjusted EBITDA[1] *R12M, multiple*			*1.3*	*1.4*	*1.3*	*1.1*

1) See Note 6 Adjustment items for items affecting comparability and Note 8 for alternative performance measures

Sustainability developments

This interim report reflects Getinge's double materiality assessment and is based on the ESRS structure to present the company's impact, risks and opportunities from a social, environmental and governance perspective. The purpose of the sustainability KPIs is to monitor trends over time. Getinge continuously work to minimize the negative impact on people and the environment and to generate sustainable value for customers, employees and other stakeholders.

- Getinge's energy efficiency measures are continuing to yield results in terms of both energy consumption and lower Scope 1 & 2 emissions from production facilities. The continued increase in the share of renewable electricity and gas also contributed to lower emissions in the quarter.
- Water consumption is mainly related to testing in production and therefore varies over time. One of the reasons for the rising trend in the outcome for R12 June 2026 was increased production.
- The employee engagement index was updated with the results of the employee survey conducted in Q2 2026. The outcome was 74, which reflects a continued positive trend and resulted in a score of 73.5 for employee engagement for R12 Jun 2026.
- The Work Related Accident Rate (WRAR) outcome for R12 Jun 2026 continued to show a positive trend.
- From 2026, the definition of the regulatory compliance KPI has been revised to focus on major observations from regulators and notified bodies only. The KPI increased slightly in R12 Jun 2026 due to the date that the audits were performed.
- The outcome for training in business ethics was a strong positive trend, with 96% of employees having completed Getinge's new Code of Conduct workshop to date.

Key areas	R12 Jun 2026[1]	R12 Jun 2025[1]	Δ, %[2]	Jan-Dec 2025	Δ, %[3]
Environment, Climate & Energy					
Scope 1 & 2 GHG emissions in production, ton CO_2 equivalents[9]	4,502	5,300	-15.1	4,913	-8.4
Total energy consumption in production, MWh[9]	77,599	83,137	-6.7	80,887	-4.1
Percentage of renewable energy of total energy, %[9]	71	67	4.0*	69	2.0*
Water consumption in sites located in water scarce areas, m^3 [4, 9]	124,003	105,316	17.7	114,691	8.1
Social					
Own workforce					
Employee engagement, %[5]	73.5	72	1.5*	73	0.5*
Percentage of female employees, %[6]	38.4	38.2	0.2*	38.2	0.2*
Percentage of female managers, %[6]	34.8	34.6	0.2*	34.1	0.7*
Work Related Accident Rate, WRAR[9]	0.50	0.86	-41.9	0.59	-15.3
Consumers and end-users					
Regulatory compliance, audit findings per audit for quality systems[7]	0.8	-	-	0.7	12.3
Product quality, field actions per SEK billion in net revenue	0.9	1.3	-30	1.0	-6.2
Online customer training[10]	52,637	50,511	4.2	53,238	-1.1
Governance					
Business ethics					
Percentage of employees who completed training in business ethics, %[8]	96	-	-	-	-

*) Change in percentage points
1) R12 = Rolling 12 months
2) Index R12 Jun 2026/ R12 Jun 2025
3) Index R12 Jun 2026/ Jan-Dec 2025
4) The production sites in scope are those located in areas with high or extremely high water stress according to the WRI Water Risk Atlas tool Acqueduct, which are eight sites.
5) Measured and updated every six months
6) Amount at end of period
7) Data available from 2025
8) Outcome for Jan-Jun 2026. From 2026, the KPI represents the percentage of employees who completed Getinge's new Code of Conduct workshop. The outcome for the previous training in business ethics was 92% for the full-year 2025
9) Four legal entities, joined the Group by acquisition, and data was updated 2025. See Getinge's Annual Report 2025 for more information
10) Data was recalculated in 2024. See Getinge's 2024 Sustainability Report for more details





Acute Care Therapies

Acute Care Therapies offers world-leading solutions for life support in acute health conditions. The offering includes solutions for cardiovascular procedures, efficient handling of organs for transplantation and a broad selection of products and therapies for intensive care.

- The organic order intake for Acute Care Therapies increased, primarily in ECLS therapy consumables, stents and EVH.
- Geographically, the organic order intake grew by double digits in EMEA, following a strong performance in Poland and Italy in such areas as ventilators.

- Acute Care Therapies increased its net sales organically, primarily due to sales of stents, ECLS therapy consumables, as well as intra-aortic balloon pumps and consumables in the Cardiac Assist segment.
- Sales grew organically in all regions. In EMEA, Poland and Sweden were the main contributors, while the US drove the positive trend in Americas.
- Recurring revenue increased primarily as a result of service, ECLS therapy consumables and stents. Capital goods also rose, mainly due to contributions from Cardiac Assist.

- The adjusted gross margin improved by 7.0 percentage points, largely due to the tariff refund, higher sales and continued successful price adjustments.
- Adjusted selling and administrative expenses increased organically by 8.4%. Inorganically, these expenses increased by 6.0%.
- Adjusted EBITA for Acute Care Therapies rose by SEK 354 M, mainly due to improved gross profit. The margin increased by 7.5 percentage points.
- Currency effects impacted sales by SEK -131 M, adjusted gross profit by SEK -89 M and adjusted EBITA by SEK -58 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	2,376	2,372	*3.9*	4,572	5,119	*-2.0*	9,244	9,791
APAC	853	872	*-0.4*	1,748	1,821	*4.6*	3,510	3,583
EMEA	1,261	1,138	*16.3*	2,426	2,366	*10.2*	4,906	4,846
Total	**4,490**	**4,382**	***6.2***	**8,747**	**9,307**	***2.3***	**17,660**	**18,220**

Net sales regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	2,406	2,418	*3.1*	4,495	5,068	*-3.0*	9,319	9,893
APAC	895	891	*4.1*	1,743	1,915	*-0.2*	3,757	3,928
EMEA	1,251	1,171	*13.7*	2,327	2,272	*10.4*	4,909	4,854
Total	**4,552**	**4,480**	***6.0***	**8,565**	**9,255**	***0.8***	**17,985**	**18,675**

Net sales specified by capital goods and recurring revenue, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Capital goods	927	945	*2.5*	1,652	1,982	*-9.4*	3,938	4,267
Recurring revenue[1)]	3,626	3,535	*6.9*	6,912	7,273	*3.6*	14,047	14,407
Total	**4,552**	**4,480**	***6.0***	**8,565**	**9,255**	***0.8***	**17,985**	**18,675**

1) Consumables, service and spare parts

Earnings trend[1)]

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Net sales	**4,552**	**4,480**	**8,565**	**9,255**	**17,985**	**18,675**
Adjusted gross profit	**2,959**	**2,601**	**5,373**	**5,495**	**10,775**	**10,897**
Margin, %	*65.0*	*58.0*	*62.7*	*59.4*	*59.9*	*58.4*
Adjusted EBITDA	**1,412**	**1,062**	**2,374**	**2,298**	**4,692**	**4,616**
Margin, %	*31.0*	*23.7*	*27.7*	*24.8*	*26.1*	*24.7*
Depreciation, amortization and write-downs of intangible assets and tangible assets	-210	-214	-409	-438	-823	-853
Adjusted EBITA	**1,202**	**848**	**1,965**	**1,860**	**3,868**	**3,763**
Margin, %	*26.4*	*18.9*	*22.9*	*20.1*	*21.5*	*20.2*

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- Vasoview Hemopro 3 was launched, the latest evolution of Getinge's EVH platform. The product is launching in the US and Getinge is planning a phased expansion outside the US based on regulatory approvals and market readiness.
- A 510(k) application for the Cardiosave intra-aortic balloon pump was submitted to the US FDA.

Life Science

Life Science offers a comprehensive range of equipment, technical expertise and consultation to prevent contamination in pharmaceutical and medical device production and with the aim to strengthen integrity of results in biomedical research.

- Life Science's organic order intake rose sharply during the quarter, following double-digit growth in Sterile Transfer and Bio-Processing. WIS continued to decline as a result of geopolitical uncertainty and the continued challenging investment climate for pharma.
- The organic order intake increased in all regions on the back of the strong performance in Sterile Transfer and Bio-Processing.

- Organic net sales for Life Science fell slightly despite robust growth in all product categories, except for WIS.
- Organic sales increased in EMEA and APAC, but declined in Americas, where other product categories were unable to offset the negative trend in WIS.
- Recurring revenue continued to show double-digit growth, while capital goods did the opposite. Sterile Transfer contributed strongly to both categories, where sales of the capital good DPTE®-Alpha Port enables future sales of the consumable DPTE®-BetaBag. The decline in capital goods was entirely driven by WIS.

- The adjusted gross margin increased by 1.8 percentage points, mainly attributable to a favorable mix, price adjustments and the tariff refund.
- Adjusted selling and administrative expenses increased organically by 3.9%. Inorganically, these expenses increased by 2.8%.
- Life Science's adjusted EBITA increased by SEK 23 M, mainly attributable to improved gross profit. The margin increased by 2.3 percentage points.
- Currency effects impacted sales by SEK -19 M, adjusted gross profit by SEK -22 M and adjusted EBITA by SEK -19 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	503	374	*40.6*	862	710	*32.5*	1,621	1,469
APAC	150	146	*5.4*	288	254	*22.5*	554	520
EMEA	586	535	*11.1*	998	1,068	*-3.8*	2,193	2,263
Total	**1,240**	**1,054**	***20.8***	**2,148**	**2,032**	***12.2***	**4,368**	**4,252**

Net sales regions, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Americas	394	420	*-3.7*	775	788	*6.9*	1,646	1,660
APAC	142	138	*5.5*	245	246	*7.5*	602	603
EMEA	566	566	*0.9*	1,084	1,039	*7.4*	2,281	2,235
Total	**1,101**	**1,123**	***-0.2***	**2,104**	**2,073**	***7.2***	**4,529**	**4,498**

Net sales specified by capital goods and recurring revenue, SEK M	Apr-Jun 2026	Apr-Jun 2025	*Org Δ, %*	Jan-Jun 2026	Jan-Jun 2025	*Org Δ, %*	R12 Jun 2026	Jan-Dec 2025
Capital goods	355	502	*-28.5*	681	814	*-11.7*	1,740	1,872
Recurring revenue[1)]	747	621	*22.6*	1,423	1,259	*19.4*	2,790	2,626
Total	**1,101**	**1,123**	***-0.2***	**2,104**	**2,073**	***7.2***	**4,529**	**4,498**

1) Consumables, service and spare parts

Earnings trend[1)]

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	R12 Jun 2026	Jan-Dec 2025
Net sales	**1,101**	**1,123**	**2,104**	**2,073**	**4,529**	**4,498**
Adjusted gross profit	**445**	**433**	**822**	**808**	**1,691**	**1,676**
Margin, %	*40.4*	*38.6*	*39.1*	*39.0*	*37.3*	*37.3*
Adjusted EBITDA	**200**	**179**	**345**	**287**	**770**	**712**
Margin, %	*18.1*	*15.9*	*16.4*	*13.8*	*17.0*	*15.8*
Depreciation, amortization and write-downs of intangible assets and tangible assets	-53	-55	-103	-111	-214	-222
Adjusted EBITA	**146**	**123**	**243**	**176**	**556**	**490**
Margin, %	*13.3*	*11.0*	*11.5*	*8.5*	*12.3*	*10.9*

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- Sterile Transfer continued its robust growth in the quarter, and the segment is benefitting from two clear market drivers: the rapid increase in the production of GLP-1 drugs, and the stricter requirements for aseptic processing under the EU GMP Annex 1. Both of these factors are driving customer demand for high-performance sterile transfer solutions – a product category where Getinge is a market leader.
- The market climate for the WIS product segment appears to be gradually improving, but customers' longer decision-making processes and strong competition are delaying order placement. However, share of tenders won by Getinge remains stable. The product offering is being renewed and expanded to further enhance competitiveness, drive sustainable growth, and support a gradual recovery in the order intake.

Surgical Workflows

Surgical Workflows offers products and solutions to serve as an end-to-end partner for optimizing the quality, safety and capacity usage of the sterile supply departments and operating rooms.

- The organic order intake for Surgical Workflows increased slightly, driven by a strong performance in Infection Control, while Digital Health Solutions and Surgical Workplaces noted a decline.
- Growth was particularly strong in North America, mainly in capital goods in Infection Control. The decline in APAC was mainly related to operating tables.

- In Surgical Workflows, organic net sales rose following growth in Surgical Workplaces as well as service and consumables in Infection Control.
- Geographically, growth was high in Americas and EMEA, mainly in Infection Control and Surgical Workplaces. All product categories in APAC declined.
- Stable growth in both capital goods and recurring revenue, primarily in service.

- The adjusted gross margin increased by 1.9 percentage points, mainly due to the tariff refund, price adjustments and higher sales.
- Adjusted selling and administrative expenses increased organically by 2.7%, mainly as a result of higher sales activities. Inorganically, these expenses increased by 1.6%.
- Adjusted EBITA for Surgical Workflows increased by SEK 96 M, mainly due to improved gross profit. The margin improved by 3.3 percentage points.
- Currency effects impacted sales by SEK -56 M, adjusted gross profit by SEK -15 M and adjusted EBITA by SEK -1 M compared with last year.

Order intake and net sales

Order intake regions, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	***Org Δ, %***	**Jan-Jun 2026**	**Jan-Jun 2025**	***Org Δ, %***	**R12 Jun 2026**	**Jan-Dec 2025**
Americas	1,067	1,022	*6.3*	2,192	2,024	*17.8*	4,337	4,168
APAC	554	619	*-6.4*	928	1,092	*-7.7*	2,044	2,208
EMEA	1,316	1,283	*0.5*	2,592	2,539	*4.6*	5,230	5,176
Total	**2,938**	**2,924**	***1.1***	**5,712**	**5,655**	***6.9***	**11,611**	**11,553**

Net sales regions, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	***Org Δ, %***	**Jan-Jun 2026**	**Jan-Jun 2025**	***Org Δ, %***	**R12 Jun 2026**	**Jan-Dec 2025**
Americas	1,075	1,009	*9.3*	2,058	2,037	*9.9*	4,154	4,133
APAC	450	524	*-11.5*	853	1,034	*-10.9*	2,231	2,412
EMEA	1,202	1,101	*7.3*	2,243	2,157	*5.9*	5,337	5,251
Total	**2,727**	**2,634**	***4.3***	**5,155**	**5,229**	***4.1***	**11,722**	**11,796**

Net sales specified by capital goods and recurring revenue, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	***Org Δ, %***	**Jan-Jun 2026**	**Jan-Jun 2025**	***Org Δ, %***	**R12 Jun 2026**	**Jan-Dec 2025**
Capital goods	1,214	1,182	*5.0*	2,239	2,313	*2.2*	5,754	5,829
Recurring revenue[1)]	1,514	1,452	*3.8*	2,916	2,915	*5.7*	5,968	5,967
Total	**2,727**	**2,634**	***4.3***	**5,155**	**5,229**	***4.1***	**11,722**	**11,796**

1) Consumables, service and spare parts

Earnings trend[1)]

SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Net sales	**2,727**	**2,634**	**5,155**	**5,229**	**11,722**	**11,796**
Adjusted gross profit	**1,242**	**1,149**	**2,279**	**2,217**	**5,095**	**5,034**
Margin, %	*45.5*	*43.6*	*44.2*	*42.4*	*43.5*	*42.7*
Adjusted EBITDA	**387**	**292**	**609**	**497**	**1,808**	**1,697**
Margin, %	*14.2*	*11.1*	*11.8*	*9.5*	*15.4*	*14.4*
Depreciation, amortization and write-downs of intangible assets and tangible assets	-150	-150	-296	-307	-608	-619
Adjusted EBITA	**237**	**141**	**312**	**190**	**1,200**	**1,077**
Margin, %	*8.7*	*5.4*	*6.1*	*3.6*	*10.2*	*9.1*

1) See Note 4 Depreciation, amortization and write-downs and Note 6 Adjustment items for other items affecting comparability

Events in the business area in the quarter

- With Aquadis Endo 110, the next generation of automated endoscope reprocessing is introduced to increase processing capacity by more than a third, simplify workflows and enhance safety for clinical staff.
- The launch of Fluobeam LS expands the fluorescence imaging portfolio for small-incision surgery and supports real-time visualization for procedures such as thyroid surgery and sentinel lymph node (SLN) detection in breast cancer.
- The acquisition of Pennamed, a UK-based distributor of endoscopic consumables, strengthens Getinge's endoscopy offering in the UK. The deal combines Pennamed's established portfolio and customer relationships with Getinge's expertise in endoscope reprocessing, infection control and washer-disinfector technology.
- A Digital OR Innovation Center was opened in Hamburg, Germany, where software development and clinical expertise are brought together to further accelerate the development of one intelligent digital ecosystem across the perioperative workflow.

Other information

Events after the end of the reporting period

The geopolitical uncertainty and changing global environment continue to dominate the market. We are monitoring developments closely and continuously assessing the potential impact on our operations.

Significant events earlier in the year

No individual events occurring in earlier quarters of the year are considered to have had, or are expected to have, a material effect on the financial statements, nor are they of such significance as to be necessary for understanding the changes in the Company's financial position and results of operations since the end of the latest financial year.

Seasonal variations

Getinge's sales and earnings are affected by seasonal variations. The highest net sales are usually generated in the fourth quarter, followed by the second, third and first quarters. The shares of sales derived from capital goods and recurring revenue also normally changes during the year, with a higher share of sales of capital goods toward the end of the year.

Transactions with related parties

Getinge carried out normal commercial transactions with companies in the Carl Bennet AB sphere, which comprised the sale and purchase of goods and services. In addition, no other significant transactions with related parties occurred during the period other than transactions with subsidiaries.

Forward-looking information

This report contains forward-looking information based on the current expectations of company management. Although management deems that the expectations presented by such forward-looking information are reasonable, no guarantee can be given that these expectations will prove correct. Accordingly, the actual future outcome could vary considerably compared with what is stated in the forward-looking information, due to such factors as changed conditions regarding finances, market and competition, changes in legal and regulatory requirements and other political measures, and fluctuations in exchange rates.

Update of Organic change key ratio

The definition of Organic change has been updated from the first quarter of 2026 to also adjust for phase-outs of product categories. The change has been made to provide a more fair presentation of underlying growth even when phase-outs are currently being made. Quarterly comparative figures for 2025, excluding the Surgical Perfusion product category, are published on Getinge's website under Reports and Presentations,
https://www.getinge.com/int/company/investors/reports-presentations/.
Surgical Perfusion's sales in 2026 are expected to decline from approximately SEK 250 M to SEK 50 M.

Getinge's financial targets 2024–2028 and dividend policy

- Average adjusted earnings per share growth: >12%*
- Getinge's dividend policy is to pay dividends of 30-50% of net profit to shareholders.

Getinge's sustainability targets

Environment

- Reduce Scope 1 and 2 emissions by 90% by 2030**

- Reduce Scope 3 emissions by 25% by 2030, and by 90% by 2050**
- Reduce energy consumption in production by 20% by 2030**
- Reduce water consumption in sites located in water scarce areas by 20% by 2030**
- No waste to landfill by 2030, excluding material required by local regulations to be landfilled

Social
- Employee engagement: >70%
- Maintain work-related accidents in relation to working hours (Work Related Accident Rate, WRAR) at less than 1.
- Ensure equal employment opportunity and non-discrimination across all levels of the organization. Follow-up % female vs male managers and employees.
- Quality regulatory compliance, audit results/inspection: <1.2 deviation

Governance
- All employees are properly trained in Business ethics

**Base year 2023*
***Base year 2021*

Risk management

Risk management

Getinge operates in a global market and has a strong presence in a large number of countries. Active risk management at all levels is important in order for Getinge to successfully continue to create innovative products and services that improve people's quality of life.

Risk management framework

Getinge's three business areas and the Global Sales and Service organization are responsible for identifying and managing risks in their respective areas. The corporate and Group support functions support these units by providing governance, developing processes and promoting synergies in their specific areas of competence. In addition, several forums and groups have been established that focus on certain areas and identify and monitor specific types of risks.

Getinge has an Enterprise Risk Management (ERM) process covering all business areas, the global sales and service organization and the corporate and Group support functions. The Executive Team evaluates the material risks identified in the ERM process and its potential impacts, and decides on actions to mitigate risks and their consequences. The results of the ERM process serve as a key basis in determining the focus areas for Corporate Internal Audit.

Risk assessment

The most relevant risks are presented in Getinge's 2025 Annual Report, meaning that the list does not constitute a complete account of all of the risks to which the Group is exposed. The risks are divided into three categories:

- **External** – risks that cannot be controlled, but that are monitored and prepared for in order to optimize outcomes and turn risks into opportunities.
- **Operational** – Risks that are largely controllable and preventable, mainly related to processes, assets and employees.
- **Strategic** – risks that make it more difficult to achieve the strategic targets. These risks are to be managed by balancing risks and the potential for maximizing advantages.

Assurance

The Board of Directors and CEO assure that the interim report provides a true and fair review of the Parent Company and the Group's operations, position and earnings and describes the material risks and uncertainties faced by the Parent Company and the Group.

Gothenburg, July 17, 2026

Johan Malmquist
Chairman,
AGM-elected Board member

Carl Bennet
Vice Chairman,
AGM-elected Board member

Johan Bygge
AGM-elected Board member

Cecilia Daun Wennborg
AGM-elected Board member

Ulrika Dellby
AGM-elected Board member

Dan Frohm
AGM-elected Board member

Mattias Perjos
President & CEO,
AGM-elected Board member

Kristian Samuelsson
AGM-elected Board member

Camilla Sylvest
AGM-elected Board member

Fredrik Brattborn
Board member
Representative of the Swedish Metalworkers' Union

Ida Ekman
Board member
Representative of Unionen

The report is unaudited.

Consolidated financial statements

Condensed consolidated income statement

SEK M	Note	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net sales	2, 3	8,381	8,238	15,824	16,557	34,969
Cost of goods sold		-3,965	-4,296	-7,802	-8,521	-18,315
Gross profit	2, 3, 4	**4,416**	**3,941**	**8,022**	**8,036**	**16,654**
Selling expenses		-1,511	-1,474	-2,941	-3,060	-6,050
Administrative expenses		-1,196	-1,135	-2,318	-2,316	-4,587
Research and development costs		-358	-343	-686	-661	-1,452
Acquisition costs		-13	-1	-31	-3	-24
Restructuring costs		-54	-26	-67	-322	-374
Other operating income and expenses		0	-94	12	-209	-379
Operating profit (EBIT)	3, 4	**1,284**	**867**	**1,991**	**1,465**	**3,789**
Net financial items	3	-133	-147	-267	-317	-644
Profit after financial items	3	**1,151**	**721**	**1,724**	**1,149**	**3,145**
Taxes		-312	-194	-482	-318	-869
Net profit for the period		**839**	**527**	**1,242**	**831**	**2,276**
Attributable to:						
Parent Company shareholders		841	524	1,242	824	2,258
Non-controlling interests		-2	3	-1	7	17
Net profit for the period		**839**	**527**	**1,242**	**831**	**2,276**
Earnings per share, SEK [1) 2)]		3.09	1.92	4.56	3.02	8.29
Weighted average number of shares for calculation of earnings per share (000s)		272,370	272,370	272,370	272,370	272,370

1) Before and after dilution
2) Attributable to the Parent Company shareholders

Consolidated statement of comprehensive income

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net profit for the period	**839**	**527**	**1,242**	**831**	**2,276**
Other comprehensive income					
Items that cannot be restated in profit for the period					
Actuarial gains/losses pertaining to defined-benefit pension plans	-36	-24	36	79	165
Tax attributable to items that cannot be restated in profit	7	5	-14	-24	-45
Items that can later be restated in profit for the period					
Translation differences	416	-888	1,391	-3,318	-4,160
Hedging of net investments	55	-98	195	-616	-754
Cash flow hedges	-10	-16	-3	-14	-5
Tax attributable to items that can be restated in profit	-9	24	-40	130	156
Other comprehensive income for the period, net after tax	**423**	**-998**	**1,567**	**-3,764**	**-4,643**
Total comprehensive income for the period	**1,262**	**-471**	**2,809**	**-2,933**	**-2,367**
Comprehensive income attributable to:					
Parent Company shareholders	1,264	-477	2,809	-2,929	-2,373
Non-controlling interests	-2	6	-0	-4	6
Total comprehensive income for the period	**1,262**	**-471**	**2,809**	**-2,933**	**-2,367**

Condensed consolidated balance sheet

SEK M	Note	June 30 2026	June 30 2025	December 31 2025
Intangible assets		35,557	34,688	33,513
Tangible assets		3,536	3,561	3,469
Right-of-use assets		1,608	1,502	1,470
Financial assets		58	31	34
Deferred tax assets		842	857	792
Total non-current assets		**41,600**	**40,639**	**39,278**
Inventories		6,840	6,793	6,018
Accounts receivable		5,087	4,785	5,782
Other current receivables		1,791	2,210	2,026
Cash and cash equivalents	7	2,052	1,945	3,401
Total current assets		**15,769**	**15,733**	**17,227**
TOTAL ASSETS		**57,370**	**56,371**	**56,505**
Equity		**30,997**	**29,019**	**29,494**
Provisions for pensions, interest-bearing	7	2,443	2,500	2,358
Lease liabilities, long-term	7	1,147	1,065	1,029
Interest-bearing liabilities, long-term	7	7,942	7,910	7,893
Deferred tax liabilities		1,915	1,917	1,754
Other provisions, long-term		408	591	485
Other non-interest-bearing liabilities, long-term		483	517	452
Total long-term liabilities		**14,339**	**14,499**	**13,970**
Lease liabilities, current	7	477	445	452
Interest-bearing liabilities, current	7	1,534	1,749	1,510
Other provisions, current		1,613	1,723	1,564
Accounts payable		2,090	2,044	2,118
Other non-interest-bearing liabilities, current		6,320	6,891	7,398
Total current liabilities		**12,034**	**12,853**	**13,042**
TOTAL EQUITY AND LIABILITIES		**57,370**	**56,371**	**56,505**

Changes in equity for the Group

SEK M	Share capital	Other capital provided	Reserves[1)]	Retained earnings	Total	Non-controlling interests	Total equity
Opening balance at January 1, 2026	**136**	**6,789**	**1,000**	**21,504**	**29,430**	**64**	**29,494**
Total comprehensive income for the period	-	-	1,544	1,265	**2,809**	-0	2,809
Dividend	-	-	-	-1,294	**-1,294**	-12	-1,305
Closing balance at June 30, 2026	**136**	**6,789**	**2,545**	**21,475**	**30,945**	**52**	**30,997**
Opening balance at January 1, 2025	**136**	**6,789**	**5,752**	**20,328**	**33,005**	**205**	**33,210**
Total comprehensive income for the period	-	-	-3,807	878	**-2,929**	-4	**-2,933**
Dividend	-	-	-	-1,253	**-1,253**	-6	**-1,259**
Closing balance at June 30, 2025	**136**	**6,789**	**1,945**	**19,953**	**28,823**	**195**	**29,019**
Opening balance at January 1, 2025	**136**	**6,789**	**5,752**	**20,328**	**33,005**	**205**	**33,210**
Total comprehensive income for the period	-	-	-4,752	2,378	**-2,373**	6	**-2,367**
Dividend	-	-	-	-1,253	**-1,253**	-14	**-1,267**
Transactions with non-controlling interests	-	-	-	50	**50**	-133	**-83**
Closing balance at December 31, 2025	**136**	**6,789**	**1,000**	**21,504**	**29,430**	**64**	**29,494**

1) Reserves pertain to cash flow hedges, hedges of net investments and translation differences.

Condensed consolidated cash flow statement

SEK M	Note	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Operating activities						
Operating profit (EBIT)		1,284	867	1,991	1,465	3,789
Add-back of depreciation, amortization and write-downs	4	505	515	989	1,081	2,250
Other non-cash items		0	6	1	17	164
Add-back of restructuring costs[1]		54	27	67	303	362
Paid restructuring costs		-59	-25	-126	-130	-338
Financial items[2]		-134	-145	-251	-263	-516
Taxes paid		-183	-191	-341	-286	-574
Cash flow before changes in working capital		**1,466**	**1,054**	**2,330**	**2,186**	**5,137**
Changes in working capital						
Inventories		-167	-277	-514	-961	-465
Operating receivables		-101	200	1,070	966	-218
Operating liabilities		94	-137	-488	-881	-504
Cash flow from operating activities		**1,291**	**841**	**2,398**	**1,311**	**3,949**
Investing activities						
Acquisition of operations	9	-1,437	-1,489	-1,437	-1,580	-1,663
Investments in intangible assets and tangible assets		-296	-335	-564	-648	-1,314
Divestment of non-current assets		5	4	9	7	17
Cash flow from investing activities		**-1,727**	**-1,820**	**-1,991**	**-2,221**	**-2,960**
Financing activities						
Change in interest-bearing liabilities		-54	-88	-121	1,178	1,000
Depreciation of lease liabilities		-132	-123	-254	-251	-501
Change in long-term receivables		0	1	0	-0	3
Dividend paid		-1,305	-1,259	-1,305	-1,259	-1,267
Cash flow from financing activities		**-1,491**	**-1,469**	**-1,680**	**-333**	**-765**
Cash flow for the period		**-1,927**	**-2,448**	**-1,274**	**-1,244**	**224**
Cash and cash equivalents at the beginning of the period		4,020	4,203	3,401	2,961	2,961
Translation differences		-42	190	-76	227	216
Cash and cash equivalents at the end of the period		**2,052**	**1,945**	**2,052**	**1,945**	**3,401**

1) Excluding write-downs on non-current assets
2) Of which interest paid and received in the quarter amounted to SEK -128 M (-140) and other financial items to SEK -6 M (-5)

Note 1 Accounting policies

The Group's interim report has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. For the Parent Company, the report has been prepared in accordance with the Swedish Annual Accounts Act and RFR 2. The accounting policies adopted are consistent with those applied for the 2025 Annual Report and should be read in conjunction with that Annual Report.

Forthcoming amendments to presentation and disclosures (IFRS 18)
IFRS 18 Presentation and Disclosure in Financial Statements will be applied by the Getinge Group from January 1, 2027. The standard is expected to primarily affect the presentation of the income statement, including the classification of income and expenses into the operating, investing, and financing categories, as well as the introduction of new subtotals. For Getinge, implementation is expected to result in certain reclassifications in the income statement, for example, related to the presentation of financial items, as well as discount effects on contingent considerations. The standard is not expected to impact the Group's overall earnings, cash flow or financial position. IFRS 18 also introduces expanded disclosure requirements in the form of management-defined performance measures. The Group is currently analyzing which of its key ratios will be impacted by the definition and how these are to be presented and reconciled against subtotals defined by IFRS. A detailed description of the effects of IFRS 18 will be provided in the 2026 Annual Report.

For practical reasons, the figures in this interim report have not been rounded off, which is why notes and tables may not total correct amounts. Unless otherwise specified, all figures pertain to SEK M and figures in parentheses pertain to the year-earlier period. The interim report provides alternative performance measures for monitoring the Group's operations.

Note 2 Net sales

Net sales, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Capital goods	**2,495**	**2,629**	**4,573**	**5,110**	**11,968**
Recurring revenue					
Product sales	4,182	3,993	7,970	8,142	16,185
Service assignments incl. spare parts	1,704	1,616	3,281	3,305	6,815
Total recurring revenue	**5,886**	**5,609**	**11,251**	**11,448**	**23,001**
Total	**8,381**	**8,238**	**15,824**	**16,557**	**34,969**

Net sales, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Revenue recognized at a point in time					
Acute Care Therapies	4,261	4,205	8,006	8,709	17,499
Life Science	870	802	1,698	1,602	3,386
Surgical Workflows	2,270	2,127	4,193	4,217	9,626
Total revenue recognized at a point in time	**7,401**	**7,134**	**13,896**	**14,528**	**30,512**
Revenue recognized over time					
Acute Care Therapies					
Service	268	251	511	504	1,068
Profit from ongoing projects	-0	0	-	0	-
Other revenue recognized over time	24	25	48	43	108
Total Acute Care Therapies	**291**	**276**	**559**	**546**	**1,176**
Life Science					
Service	72	72	135	135	260
Profit from ongoing projects	160	248	271	336	852
Other revenue recognized over time	-	0	-	0	0
Total Life Science	**232**	**321**	**406**	**471**	**1,112**
Surgical Workflows					
Service	420	447	874	892	1,870
Profit from ongoing projects	3	31	18	60	139
Other revenue recognized over time	35	30	70	60	160
Total Surgical Workflows	**457**	**507**	**962**	**1,012**	**2,170**
Total revenue recognized over time	**980**	**1,104**	**1,927**	**2,029**	**4,457**
Total revenue recognized at a point in time and over time	**8,381**	**8,238**	**15,824**	**16,557**	**34,969**

For further information about the distribution of sales for each business area, see pages 6-8.

Note 3 Segment overview

Net sales, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acute Care Therapies	4,552	4,480	8,565	9,255	18,675
Life Science	1,101	1,123	2,104	2,073	4,498
Surgical Workflows	2,727	2,634	5,155	5,229	11,796
Total	**8,381**	**8,238**	**15,824**	**16,557**	**34,969**

Gross profit, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acute Care Therapies	2,843	2,478	5,148	5,247	10,420
Life Science	416	401	767	747	1,556
Surgical Workflows	1,158	1,062	2,108	2,041	4,679
Total	**4,416**	**3,941**	**8,022**	**8,036**	**16,654**

Operating profit (EBIT), SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acute Care Therapies	1,105	775	1,807	1,467	3,021
Life Science	133	98	214	136	470
Surgical Workflows	167	120	219	99	773
Group functions and other (incl. eliminations)[1)]	-121	-125	-249	-237	-474
Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**3,789**
Net financial items	-133	-147	-267	-317	-644
Profit after financial items	**1,151**	**721**	**1,724**	**1,149**	**3,145**

1) Group functions and other refer mainly to central functions such as finance, communication, HR and other items, such as eliminations.

Net sales, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
EMEA	3,020	2,838	5,655	5,468	12,340
of which, Sweden	*155*	*184*	*306*	*323*	*648*
Americas	3,875	3,847	7,328	7,894	15,686
of which, USA	*3,503*	*3,437*	*6,641*	*7,129*	*14,157*
APAC	1,486	1,553	2,842	3,195	6,943
Total	**8,381**	**8,238**	**15,824**	**16,557**	**34,969**

Note 4 Depreciation, amortization and write-downs

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acquired intangible assets	-93	-94	-180	-201	-434
Intangible assets	-134	-150	-264	-314	-643
Right-of-use assets	-139	-128	-265	-264	-523
Tangible assets	-138	-142	-280	-301	-650
Total	**-505**	**-515**	**-989**	**-1,081**	**-2,250**
Write-downs included in total	*-1*	*1*	*-1*	*-19*	*-166*

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Cost of goods sold	-225	-241	-447	-483	-953
Selling expenses	-166	-157	-319	-338	-705
Administrative expenses	-93	-100	-182	-206	-405
Research and development costs	-21	-17	-40	-34	-175
Restructuring costs	-	1	-	-19	-12
Total	**-505**	**-515**	**-989**	**-1,081**	**-2,250**
Write-downs included in total	*-1*	*1*	*-1*	*-19*	*-166*

Note 5 Quarterly results

SEK M	Apr-Jun 2026	Jan-Mar 2026	Oct-Dec 2025	Jul-Sep 2025	Apr-Jun 2025	Jan-Mar 2025	Oct-Dec 2024	Jul-Sep 2024
Net sales	8,381	7,443	10,186	8,226	8,238	8,320	11,071	7,870
Cost of goods sold	-3,965	-3,837	-5,382	-4,411	-4,296	-4,225	-6,018	-4,315
Gross profit	**4,416**	**3,606**	**4,803**	**3,815**	**3,941**	**4,095**	**5,053**	**3,556**
Operating expenses	-3,132	-2,899	-3,432	-2,863	-3,074	-3,497	-3,969	-3,372
Operating profit (EBIT)	**1,284**	**707**	**1,371**	**952**	**867**	**598**	**1,084**	**184**
Net financial items	-133	-135	-164	-163	-147	-170	-173	-152
Profit after financial items	**1,151**	**573**	**1,207**	**789**	**721**	**428**	**911**	**32**
Taxes	-312	-170	-338	-214	-194	-124	-243	-24
Net profit for the period	**839**	**402**	**869**	**576**	**527**	**304**	**668**	**8**

Note 6 Adjustment items

Adjusted EBITA, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acute Care Therapies	1,202	848	1,965	1,860	3,763
Life Science	146	123	243	176	490
Surgical Workflows	237	141	312	190	1,077
Group functions and other (incl. eliminations)	-108	-124	-218	-234	-450
Total	**1,478**	**989**	**2,302**	**1,992**	**4,880**

Adjustments of EBITA, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Specification of items affecting comparability that impact EBITA					
Restructuring costs, Acute Care Therapies	-8	-15	-13	-266	-293
Restructuring costs, Life Science	-1	-12	-5	-13	-22
Restructuring costs, Surgical Workflows	-45	1	-49	-44	-59
Write-down of R&D, Acute Care Therapies	-	-	-	-	-28
Write-down of R&D, Surgical Workflows	-	-	-	-	-107
Increased provision for contingent consideration, Acute Care Therapies[1)]	-	-	-	-	-179
Dissolution of provisions for contingent consideration, Life Science[1)]	-	-	-	-	55
Other, Acute Care Therapies	-33	-	-33	-	-
Group functions and other (incl. eliminations)	-13	-1	-31	-3	-24
Total	**-101**	**-28**	**-131**	**-325**	**-656**
Items affecting comparability per segment					
Acute Care Therapies	-41	-15	-46	-266	-500
Life Science	-1	-12	-5	-13	33
Surgical Workflows	-45	1	-49	-44	-166
Group functions and other (incl. eliminations)	-13	-1	-31	-3	-24
Total	**-101**	**-28**	**-131**	**-325**	**-656**

1) Reported in Other operating income and operating expenses

EBITA, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Acute Care Therapies	1,161	834	1,919	1,594	3,264
Life Science	146	111	238	164	523
Surgical Workflows	192	142	263	146	911
Group functions and other (incl. eliminations)	-121	-125	-249	-237	-474
Total	**1,377**	**961**	**2,171**	**1,667**	**4,223**

Adjustments of EBIT, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Items affecting comparability that impact EBITA (according to above)	-101	-28	-131	-325	-656
Items affecting comparability that impact EBIT but not EBITA[1)]	-	-	-	-	-48
Total	**-101**	**-28**	**-131**	**-325**	**-704**

1) Write-down of acquired intangible assets, Surgical Workflows. Reported in Operating expenses

Effect of adjustment of tax, SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Amortization and write-down of acquired intangible assets[1]	93	94	180	201	386
Items affecting comparability	101	28	131	325	704
Adjustment items, total	**194**	**122**	**311**	**527**	**1,091**
Tax on adjustment items[2]	-57	-33	-86	-145	-273
Adjustment for tax items affecting comparability	-	-	-	-	-
Total	**-57**	**-33**	**-86**	**-145**	**-273**

1) Excluding write-downs classified as items affecting comparability
2) Tax effect on tax deductible adjustment items

Note 7 Consolidated net interest-bearing debt

SEK M	June 30 2026	June 30 2025	December 31 2025
Interest-bearing liabilities, current	1,534	1,749	1,510
Interest-bearing liabilities, long-term	7,942	7,910	7,893
Provisions for pensions, interest-bearing	2,443	2,500	2,358
Lease liabilities, current	477	445	452
Lease liabilities, long-term	1,147	1,065	1,029
Interest-bearing liabilities	**13,543**	**13,669**	**13,241**
Less cash and cash equivalents	-2,052	-1,945	-3,401
Net interest-bearing cash/debt	**11,492**	**11,724**	**9,840**

Note 8 Key figures for the Group

Financial and operative key figures	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Key figures based on Getinge's financial targets					
Adjusted earnings per share[1], SEK	3.59	2.25	5.39	4.43	11.29
Growth in adjusted earnings per share[1], %	59.6	-1.7	21.6	5.5	-3.7
Other operative and financial key figures					
Organic growth in order intake, %	6.2	4.4	5.0	3.6	3.5
Organic growth in net sales, %	4.6	4.1	2.7	5.1	4.9
Gross margin, %	52.7	47.8	50.7	48.5	47.6
Selling expenses, % of net sales	18.0	17.9	18.6	18.5	17.3
Administrative expenses, % of net sales	14.3	13.8	14.6	14.0	13.1
Research and development costs, gross as a % of net sales	6.0	6.2	6.2	6.1	6.0
Operating margin, %	15.3	10.5	12.6	8.9	10.8
EBITDA, SEK M	1,793	1,382	2,984	2,546	6,039
Average number of shares, thousands	272,370	272,370	272,370	272,370	272,370
Number of shares at the end of the period, thousands	272,370	272,370	272,370	272,370	272,370
Interest-coverage ratio, multiple			12.3	11.6	11.2
Net debt/equity ratio, multiple			0.37	0.4	0.33
Net debt/Rolling 12m adjusted EBITDA, multiple			1.7	1.7	1.5
Capital employed, SEK M			40,662	41,463	40,934
Return on capital employed, %			11.9	11.2	11.0
Return on equity, %			9.0	4.9	7.5
Equity/assets ratio, %			54.0	51.5	52.2
Equity per share, SEK			113.80	106.54	108.28
Number of employees			11,758	11,874	11,670

1) Before and after dilution

Alternative performance measures

Alternative performance measures refer to financial measures used by the company's management and investors to evaluate the Group's earnings and financial position and that cannot be directly read or derived from the financial statements. These financial measures are intended to facilitate analysis of the Group's performance. Accordingly, the alternative performance measures should be considered a supplement to the financial statements prepared in accordance with IFRS. The financial measures recognized in this report may differ from similar measures used by other companies.

Calculation of organic net sales	**Apr-Jun 2026**	**Jan-Jun 2026**
Net sales 2025	**8,238**	**16,557**
Adjustment of:		
Divested operations and products as well as products being phased out, in the comparative period	-63	-122
Net sales 2025 adjusted for divested operations and products	**8,174**	**16,435**
Net sales 2026	**8,381**	**15,824**
Adjustment of:		
Currency translation	206	1 107
Acquired and divested operations and products as well as products being phased out	-38	-55
Net sales, organic, 2026	**8,549**	**16,875**

Adjusted gross profit, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Gross profit	**4,416**	**3,941**	**8,022**	**8,036**	**16,641**	**16,654**
Add-back of:						
Depreciation, amortization and write-downs of intangible assets and tangible assets	229	241	451	483	920	953
Other items affecting comparability	-	-	-	-	-	-
Adjustment for write-downs included in other items affecting comparability	-	-	-	-	-	-
Adjusted gross profit	**4,645**	**4,183**	**8,473**	**8,519**	**17,561**	**17,607**

Adjusted EBITDA, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**4,315**	**3,789**
Add-back of:						
Depreciation, amortization and write-downs of intangible assets and tangible assets	415	421	813	880	1,797	1,864
Amortization and write-down of acquired intangible assets	93	94	180	201	365	386
Other items affecting comparability	33	-	33	-	340	307
Acquisition and restructuring costs	68	28	98	325	170	397
Adjustment for write-downs included in other items affecting comparability and restructuring costs	-	1	-	-19	-143	-162
Adjusted EBITDA	**1,893**	**1,410**	**3,115**	**2,852**	**6,844**	**6,581**

Adjusted EBITA, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**4,315**	**3,789**
Add-back of:						
Amortization and write-down of acquired intangible assets	93	94	180	201	365	386
Other items affecting comparability	33	-	33	-	340	307
Acquisition and restructuring costs	68	28	98	325	170	397
Adjusted EBITA	**1,478**	**989**	**2,302**	**1,992**	**5,190**	**4,880**

Adjusted EBIT, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Operating profit (EBIT)	**1,284**	**867**	**1,991**	**1,465**	**4,315**	**3,789**
Add-back of:						
Other items affecting comparability	33	-	33	-	340	307
Acquisition and restructuring costs	68	28	98	325	170	397
Adjusted EBIT	**1,384**	**895**	**2,122**	**1,791**	**4,825**	**4,494**

Adjusted net profit for the period, SEK M	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Net profit for the period	**839**	**527**	**1,242**	**831**	**2,687**	**2,276**
Add-back of:						
Amortization and write-down of acquired intangible assets	93	94	180	201	365	386
Other items affecting comparability	33	-	33	-	340	307

Acquisition and restructuring costs	68	28	98	325	170	397
Tax items affecting comparability	-	-	-	-	-	-
Tax on add-back items	-57	-33	-86	-145	-215	-273
Adjusted net profit for the period	**976**	**616**	**1,466**	**1,213**	**3,347**	**3,093**

The calculation of adjusted earnings per share, before and after dilution, attributable to Parent Company shareholders, is based on the following information:	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Earnings (numerator), SEK M						
Adjusted net profit for the period	976	616	1,466	1,213	3,347	3,093
Adjusted net profit for the period attributable to non-controlling interest	2	-3	1	-7	-10	-17
Adjusted net profit for the period attributable to the Parent Company shareholders, which forms the basis for calculation of adjusted earnings per share	**978**	**613**	**1,467**	**1,205**	**3,337**	**3,076**
Number of shares (denominator)	**Apr-Jun 2026**	**Apr-Jun 2025**	**Jan-Jun 2026**	**Jan-Jun 2025**	**R12 Jun 2026**	**Jan-Dec 2025**
Weighted average number of ordinary shares for calculation of adjusted earnings per share (thousands)	272,370	272,370	272,370	272,370	272,370	272,370
Adjusted earnings per share, SEK	**3.59**	**2.25**	**5.39**	**4.43**	**12.25**	**11.29**

The calculation of adjusted EBITA margin, adjusted for currency impact and tariff costs is based on the following information:	**Apr-Jun 2026**	**Jan-Jun 2026**
Adjusted EBITA (numerator), SEK M		
Adjusted EBITA	1,478	2,302
Add-back of:		
Currency impact	73	194
Tariffs costs	-244	-140
Adjusted EBITA, adjusted for currency impact and tariff costs	**1,307**	**2,356**
Net sales (denominator)	**Apr-Jun 2026**	**Jan-Jun 2026**
Net sales	8,381	15,824
Add-back of:		
Currency impact	206	1,107
Net sales, adjusted for currency impact	**8,587**	**16,930**
Adjusted EBITA margin, adjusted for currency impact and tariff costs, %	**15.2**	**13.9**

Note 9 Acquisitions

Acquisitions 2026

Net assets acquired, SEK M	**Pennamed**	**Paragonix Technologies**	**Total**
Intangible assets	241	-	241
Tangible assets	4	-	4
Inventories	13	-	13
Accounts receivable	18	-	18
Prepaid expenses	2	-	2
Cash and cash equivalents	69	-	69
Deferred tax liabilities	-60	-	-60
Accounts payable	-3	-	-3
Other non-interest-bearing liabilities	-13	-	-13
Identifiable net assets	**271**	**-**	271
Goodwill	195	-	195
Total purchase prices	**466**	**-**	**466**
Deductible and additional items			

Additional purchase prices and other adjustments	-	1,040	1,040
Cash and cash equivalents in acquired businesses	-69	-	-69
Impact on the Group's cash and cash equivalents	**397**	**1,040**	**1,437**

On April 2, 2026, Getinge acquired 100% of the shares in Pennamed Ltd., a UK-based distributor of endoscopic consumables serving the National Health Service (NHS) and independent healthcare providers. The company, founded in 2007, has 14 employees and has its headquarters in East Yorkshire, UK. The acquisition was consolidated into the Getinge Group on the acquisition date and is included in Surgical Workflows. Getinge paid approximately SEK 466 M (GBP 37 M) in cash upon completion of the acquisition. The goodwill that arose in connection with the acquisition amounted to SEK 195 M, and was primarily attributable to future customer relationships. During the period since the acquisition, the company has contributed SEK 36 M to the Group's net sales and net profit of SEK 13 M. The costs of the acquisition amounted to SEK 13 M and were charged to earnings. At the time of publication of this report, the acquisition analysis was preliminary.

An additional purchase price of SEK 1,040 M was paid in the second quarter related to the acquisition of Paragonix Technologies, which was completed in 2024.

Contingent considerations

Getinge signed agreements on contingent considerations in connection with acquisitions of assets and subsidiaries. Liabilities for these additional purchase prices are measured at fair value through profit or loss at Level 3 of the fair value hierarchy. The additional purchase prices are contingent on securing government approval for the acquired product development projects and contingent on the earnings performance of the acquired businesses. Future cash flows are discounted if the planned payment date exceeds 12 months. Assessments of future cash flows related to the contingent consideration are regularly reviewed by company management and recognized at fair value. The discount effect is recognized in profit or loss under financial items on an ongoing basis.

Contingent considerations	June 30 2026	June 30 2025	December 31 2025
Opening balance	**1,444**	**3,280**	**3,280**
Dissolution of provision	-	-	-55
Fair value adjustments recognized in profit or loss	-	5	184
Payments	-1,040	-1,599	-1,599
Discount effect	18	48	77
Translation differences	51	-397	-443
Closing balance	**474**	**1,337**	**1,444**

Parent Company financial statements

Condensed Parent Company's income statement

SEK M	Apr-Jun 2026	Apr-Jun 2025	Jan-Jun 2026	Jan-Jun 2025	Jan-Dec 2025
Net sales	84	75	179	182	348
Administrative expenses	-100	-108	-238	-196	-397
Operating profit/loss	**-16**	**-33**	**-59**	**-14**	**-49**
Result from participations in Group companies[1)]	1,429	2,091	1,429	2,091	2,134
Interest income and other similar income[2)]	2	20	7	37	55
Interest expenses and other similar expenses[2)]	-51	-58	-100	-113	-220
Profit after financial items	**1,363**	**2,020**	**1,276**	**2,001**	**1,920**
Appropriations	-	-	-	-	60
Taxes	-8	-4	1	-8	-24
Net profit/loss for the period[3)]	**1,355**	**2,016**	**1,277**	**1,993**	**1,956**

1) Primarily refers to dividends from Group companies that take place on an ongoing basis throughout the year
2) Interest income and other similar income and interest expenses and other similar expenses include exchange-rate gains and losses attributable to the translation of financial receivables and liabilities measured in foreign currencies
3) Comprehensive income for the period corresponds to net profit for the period

Condensed Parent Company’s balance sheet

SEK M	June 30 2026	June 30 2025	December 31 2025
Assets			
Tangible assets	1	2	1
Participations in Group companies	31,604	31,580	31,572
Deferred tax assets	110	102	97
Current receivables from Group companies	1,421	1,371	974
Current receivables	39	53	40
Cash and bank balances	0	2	2
Total assets	**33,175**	**33,110**	**32,687**
Equity and liabilities			
Equity	26,356	26,409	26,372
Long-term liabilities	5,395	5,093	5,394
Other provisions	27	24	18
Current liabilities to Group companies	531	512	7
Current liabilities	867	1,072	896
Total equity and liabilities	**33,175**	**33,110**	**32,687**

Definitions

Financial terms

Adjusted earnings per share: Adjusted net profit for the period attributable to Parent Company shareholders in relation to average number of shares.

Adjusted EBIT: Operating profit (EBIT) with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITA: EBITA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted EBITDA: EBITDA with add-back of acquisition and restructuring costs and other items affecting comparability.

Adjusted gross profit: Gross profit with add-back of depreciation, amortization and write-downs and other items affecting comparability.

Adjusted net profit for the period: Net profit for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs, other items affecting comparability and tax effect of add-back of income-statement items.

Adjusted profit before tax: Profit before tax for the period with add-back of amortization and write-down of acquired intangible assets, acquisition and restructuring costs and other items affecting comparability.

Capital employed: Average total assets with add-back of cash and cash equivalents, other provisions, accounts payable and other non-interest-bearing liabilities.

Capital goods: Durable products that are not consumed when used.

Currency transaction effect: Exchange of current year's volumes of foreign currency at this year's exchange rates, compared with the exchange rates in the preceding year.

Earnings per share: Net profit attributable to Parent Company shareholders in relation to average number of shares.

EBIT: Operating profit.

EBITA margin: EBITA in relation to net sales.

EBITA: Operating profit (EBIT) before add-back of amortization and write-down of acquired intangible assets.

EBITDA margin: EBITDA in relation to net sales.

EBITDA: Operating profit (EBIT) with add-back of amortization, depreciation and write-downs.

Equity per share: Equity in relation to the number of shares at the end of the period.

Equity/assets ratio: Equity in relation to total assets.

Free cash flow: Cash flow from operating activities and investing activities, excluding acquisitions and divestment of operations.

Gross margin: Gross profit in relation to net sales.

Interest-coverage ratio: Rolling 12 months' adjusted EBITDA in relation to rolling 12 months' net interest.

Items affecting comparability: Acquisition and restructuring costs and other items affecting comparability. Other items affecting comparability are significant revenue/expenses that impact comparability between accounting periods. These items include, but are not limited to, write-downs, disputes and major gains and losses attributable to divestments of assets or businesses.

Net debt/equity ratio: Net interest-bearing debt in relation to equity.

Operating liabilities: Accounts payable, other provisions and other non-interest-bearing liabilities (contract liabilities, non-interest-bearing provisions for pensions and similar obligations, accrued expenses and deferred income as well as other liabilities).

Operating margin: Operating profit (EBIT) in relation to net sales.

Operating receivables: Accounts receivable and other current receivables (contract assets, prepaid expenses and accrued income, and other receivables).

Organic change: A financial change adjusted for currency, acquisitions and divestments of operations.

Adjusted to the following from first quarter of 2026:
A financial change adjusted for currency, acquisitions and
divestments of operations *and phase-out of product categories*.

Recurring revenue: Revenue from sales of products that are continuously consumed as well as service, spare parts and similar items.

Return on capital employed: Rolling 12 months' adjusted EBIT in relation to capital employed.

Return on equity: Rolling 12 months' profit after tax in relation to average equity.

Sustainability terms

Double materiality assessment: The process of identifying an organization's impacts on people and the environment and the sustainability-related financial risks and opportunities for the organization. The results are also used to determine whether a sustainability topic is to be included in the company's sustainability report.

Employee engagement: The engagement score in Getinge's employee survey.

ESRS: European Sustainability Reporting Standards.

Online customer training: The number of training courses held for customers. The total number of times a customer has completed an e-learning course or participated in a training webinar.

REC (Renewable Energy Certificates): Used to certify that electricity was generated from renewable sources.

Scope 1 & 2: Carbon emissions from production (in ton CO_2 equivalents). Scope 1 includes emissions from oil and gas consumption. Emissions from Getinge's vehicle fleet are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report. Scope 2 includes emissions from electricity, heating and cooling. Emissions from leased premises are excluded in the interim report but the amounts for the full-year are presented in the Sustainability Report.

Scope 3: Includes other indirect emissions, both upstream and downstream in the value chain, arising from activities such as freight transport, purchased goods and services, as well as emissions from the use of products sold.

WRAR (Work Related Accident Rate): The number of work related accidents divided by the number of hours worked, normalized by multiplying by 200,000 hours.

Medical terms

Autoclave: A device to eliminate microorganisms on surgical instruments, usually by high temperature with steam.

Cardiopulmonary: Pertaining or belonging to both heart and lung.

Cardiovascular: Pertaining or belonging to both heart and blood vessels.

DPTE®-BetaBags: Bag that ensures contamination-free transfer of components.

ECMO: Extracorporeal membrane oxygenation, meaning oxygenation outside the body through a membrane. Put simply, a modified cardiac and respiratory machine that exchanges oxygen and carbon dioxide, like an artificial lung.

Endoscope: Equipment for visual examination of the body's cavities, such as the stomach.

Endovascular: Vascular treatment using catheter technologies.

EVH Endoscopic Vessel Harvesting is a minimally invasive technique for removing blood vessels, for example during coronary artery bypass surgery.

Extracorporal life support (ECLS): Oxygenation of the patient's blood outside the body (extracorporeal) using advanced medical technology.

Grafts: Artificial vascular implants.

Hemodynamic monitoring: Monitoring the balance between blood pressure and blood flow.

Low temperature sterilization: A device used to sterilize surgical instruments which cannot be sterilized with high temperature steam. It is mainly used for instruments used in the minimal invasive and robotic surgery.

NAVA: Neurally Adjusted Ventilatory Assist (NAVA) identifies the electric activity that activates the diaphragm and using these signals adapts the ventilation to the patient's respiratory rhythm.

Perfusionist: A healthcare professional who operates the heart-lung machine during surgery.

Stent: A tube for endovascular widening of blood vessels.

Vascular intervention: A medical procedure conducted through vascular puncturing instead of using an open surgery method.

Ventilator: Medical device to help patients breath.

Vessel harvesting: The name of the process for removing blood vessels from the body.

WIS: The product category of washers, isolators and sterilizers.

Geographic areas

Americas: North, South and Central America.

APAC: Asia and Pacific (excluding Middle East).

EMEA: Europe, Middle East and Africa.

Teleconference

A teleconference with President & CEO Mattias Perjos and CFO Agneta Palmér will be held on July 17, 2026 at 10:00–11:00 a.m. CEST.

Fund managers, analysts and the media are invited to the teleconference.

Register via https://events.inderes.com/getinge/q2-report-2026/dial-in to participate in the teleconference. After registering, you will receive a telephone number and a conference ID to log in to the teleconference. You can ask questions verbally at the teleconference.

A presentation will be held during the telephone conference. To access the presentation, click on https://getinge.events.inderes.com/q2-report-2026. A recording will be available via https://getinge.events.inderes.com/q2-report-2026 for three years.

Financial information

Updated information on, for example, the Getinge share and corporate governance is available on Getinge's website www.getinge.com. The Annual Report, year-end report and interim reports are published in Swedish and English and are available for download at www.getinge.com. The preliminary dates for financial communication are provided below:

October 21, 2026	Q3 Report 2026
January 26, 2027	Q4 and Year-end report 2026

Contact

David Kördel, Head of Investor Relations
+46 (0)10 335 0077
david.kordel@getinge.com

This information is such that Getinge AB (publ) is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on July 17, 2026 at 8:00 a.m. CEST.

With a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions that aim to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs about 12,000 people worldwide and the products are sold in more than 135 countries.
Getinge has been listed on Nasdaq OMX Stockholm, Nordic Large Cap since 1993.

Getinge AB (publ) | Lindholmspiren 7A, 417 56 Gothenburg, Sweden | Tel: +46 (0)10 335 0000 | E-mail: info@getinge.com |
Corp. Reg. No.: 556408-5032 | www.getinge.com